Crocus Crocus Technology, the supplier of magnetic sensors and embedded memory solutions designed with Magnetic Logic Unit™ (MLU) technology, today announces it has secured $21M (€19M) in funding. All of Crocus’ historical French and international investors participated in the round … Continued
Twist Bioscience, a company focused on synthetic DNA, today announced the completion of a $37 million Series C financing. Led by Illumina, Inc., participants in the round include new investors Fidelity Management and Research Company and Foresite Capital Management LLC, … Continued
ARMO BioSciences, Inc., a clinical-stage biotechnology company, today announced positive clinical data from a Phase 1 clinical trial of AM0010, a PEGylated form of recombinant human interleukin-10 (PEG-rHuIL-10) at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting in … Continued
Today, Overstock.com, Inc. (NASDAQ: OSTK) and View, the leader in dynamic glass, announced that Overstock’s new corporate campus will incorporate View Dynamic Glass. The project marks one of the largest installations of View Dynamic Glass to date and View will … Continued
Watertown, Mass., USA, and Evry, France – May 13, 2015 – Selecta Biosciences, Inc. and Genethon today announced an ongoing research collaboration with the goal of enabling repeat dosing for gene therapies. Based on preliminary results, the companies have identified … Continued
Watertown, Mass. – May 13, 2015 – Selecta Biosciences, Inc., a clinical stage biotechnology company developing a novel class of targeted antigen-specific immune therapies, today announced that, under the terms of an existing strategic global collaboration, Sanofi (EURONEXT: SAN and … Continued
WATERTOWN, MA – April 21, 2015 – Blend Therapeutics, Inc., a biopharmaceutical company discovering and developing two distinct classes of targeted anti-cancer medicines to advance the treatment of patients with solid tumor cancers, presented preclinical data today on its lead … Continued
WATERTOWN, MA – April 21, 2015 – Blend Therapeutics, Inc., a biopharmaceutical company discovering and developing two distinct classes of targeted anti-cancer medicines to advance the treatment of patients with solid tumor cancers, presented preclinical data today on BTP-114, a … Continued
WATERTOWN, MA – April 13, 2015 – Blend Therapeutics, Inc., a biopharmaceutical company discovering and developing two distinct classes of targeted anti-cancer medicines to advance the treatment of patients with solid tumor cancers, announced today the appointment of Drew Fromkin … Continued
A rare large deal is coming together for a clean-technology manufacturing company. Investors are valuing View Inc., a maker of electronically tinting window glass, at about $750 million pre-money in a new deal that could bring as much as $100 … Continued